Johnson & Johnson (JNJ) Q4 2025 earnings summary

Executive summary

• Achieved full-year 2025 sales of $94.2B, up 6.0% year-over-year, with operational growth of 5.3% and strong performance across six key business areas: oncology, immunology, neuroscience, cardiovascular, surgery, and vision.

• Diluted EPS reached $11.03, up 90.6% year-over-year, including a $7B talc reserve reversal and special charge reversals; adjusted EPS was $10.79, up 8.1%.

• Both Innovative Medicine and MedTech segments delivered strong operational growth, driven by new product launches, commercial execution, and major acquisitions (Intra-Cellular Therapies, Halda Therapeutics).

• 28 platforms/products now generate at least $1B in annual revenue, supporting sustainable growth.

• 2025 marked by significant R&D and M&A investment ($32B+), new manufacturing facilities, and pivotal product and regulatory milestones.

Financial highlights

• Q4 2025 worldwide sales: $24.6B, up 9.1% year-over-year; U.S. sales up 7.5%, international up 11.3%.

• Q4 net earnings: $5.1B, up 49.1%; diluted EPS: $2.10, up 48.9%; adjusted net earnings: $6B; adjusted EPS: $2.46, up 20.6%.

• Full-year net earnings: $26.8B, up 90.6%; adjusted net earnings: $26.2B, up 8.1%.

• Gross margin for 2025 was 67.9%; operating margin at 34.6%.

• Free cash flow for 2025 was ~$19.7B, with $20B in cash/marketable securities and $48B in debt at year-end.

Outlook and guidance

• 2026 operational sales growth expected at 5.7%-6.7% (midpoint $100B); reported sales growth 6.2%-7.2%.

• Adjusted operational EPS guidance: $11.28-$11.48 (midpoint 5.5% growth); reported adjusted EPS: $11.53.

• Free cash flow expected to rise to ~$21B in 2026.

• 2026 adjusted pre-tax operating margin to improve by at least 50 bps.

• Guidance incorporates 53rd week, MedTech tariffs, U.S. government agreement, and higher share count.